Next Pharmaceuticals has bolstered its heart health portfolio with the purchase of the ingredient Sytrinol from KGK Synergize.
Next has purchased worldwide distribution rights, along with all patents, trademarks and scientific knowledge for Sytrinol from KGK Synergize. Sytrinol is currently sold through Proprietary Nutritionals Inc., who holds distribution rights through December 31, 2013.
"Sytrinol is an exciting addition to our portfolio of patented, proven and science based products," said Regan Miles, President of Next Pharmaceuticals. "New product acquisition is one of Next's several key growth strategies."
Heart health is a popular category, with scores of ingredients jostling for attention. And it’s a field that is likely to grow, as the aging population in the US contends with cardiovascular issue. With so much competition, what drove Next to make this addition to its portfolio?
“Next has been interested in Sytrinol for quite some time. It fits well into our company portfolio. We have several PMF (polymethoxylated flavone) products and Sytrinol has a great published clinical trial behind it and years of success in the heart health category,” Deanne Dolnick, vice president for Next, told NutraIngredients-USA.
“It is a crowded field, but Sytrinol has been on the market for quite a while & has continued to be a top seller in the category and that’s because it works.”
Weak health claims
Besides the competition, another thing that affects the marketing of heart health ingredients that purport to affect either blood pressure or cholesterol numbers is the watered down health claims that may be used. Both situations are treated with pharmaceuticals, so the best that a nutraceutical can claim to do is to support the maintenance of these readings within normal ranges.
“Technically, virtually any product can make the standard heart health claim that it supports healthy cholesterol levels in healthy individuals or whatever that mundane claim is. Unfortunately in order to make a serious health claim, many large studies must be conducted. Next is very conservative in its claims. We always have been and will continue to be with Sytrinol,” Dolnick said.
Sytrinol is a patented and proprietary formula derived from natural citrus and palm fruit extracts. It combines polymethoxylated flavones (PMFs) and delta, gamma, and alpha tocotrienols.
Clinical research has demonstrated that Sytrinol significantly aids in improving measures of total cholesterol, LDL-cholesterol, and triglycerides up to 30%, 27%, and 34%, respectively, compared to placebo. Sytrinol has also been shown to increase HDL-cholesterol and is a powerful antioxidant. Sytrinol has been granted self-affirmed GRAS (Generally Recognized as Safe) status.
Founded in 1997, Next Pharmaceuticals provides patented, science-based natural ingredients for healthy living products in the dietary supplement, food and beverage industries. Next says it has successfully developed six patented and proprietary plant extracts.
Other Next proprietary formulations include Relora for stress, stress-related eating and weight management; Seditol for improved, more restful sleep; Nexrutine for inflammation due to over-exertion and exercise; Citri-Z for heart health; Flavoxine for balanced cholesterol levels, Citrofen for joint mobility and comfort; Chromulin for balanced blood sugar; and now Sytrinol for cholesterol.